Clinical utility of combined preimplantation genetic testing methods in couples at risk of passing on beta thalassemia/hemoglobin E disease: A retrospective review from a single center.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Genetic Testing/*methods ; Hemoglobin E/*genetics ; Preimplantation Diagnosis/*methods ; beta-Globins/*genetics ; beta-Thalassemia/*genetics; Aneuploidy ; Family Characteristics ; Female ; Fertilization in Vitro/statistics & numerical data ; Humans ; Male ; Microsatellite Repeats ; Mutation ; Pregnancy ; Retrospective Studies ; Sequence Analysis, DNA

Thalassemia and hemoglobinopathy is a group of hereditary blood disorder with diverse clinical manifestation inherited by autosomal recessive manner. The Beta thalassemia/Hemoglobin E disease (HbE/βthal) causes a variable degree of hemolysis and the most severe form of HbE/βthal disease develop a lifelong transfusion-dependent anemia. Preimplantation genetic testing (PGT) is an established procedure of embryo genetic analysis to avoid the risk of passing on this particular condition from the carrier parents to their offspring. Preimplantation genetic testing for chromosomal aneuploidy (PGT-A) also facilitates the selection of embryos without chromosomal aberration resulting in the successful embryo implantation rate. Herein, we study the clinical outcome of using combined PGT-M and PGT-A in couples at risk of passing on HbE/βthal disease. The study was performed from January 2016 to December 2017. PGT-M was developed using short tandem repeat linkage analysis around the beta globin gene cluster and direct mutation testing using primer extension-based mini-sequencing. Thereafter, we recruited 15 couples at risk of passing on HbE/βthal disease who underwent a combined total of 22 IVF cycles. PGT was performed in 106 embryos with a 3.89% allele drop-out rate. Using combined PGT-M and PGT-A methods, 80% of women obtained satisfactory genetic testing results and were able to undergo embryo transfer within the first two cycles. The successful implantation rate was 64.29%. PGT accuracy was evaluated by prenatal and postnatal genetic confirmation and 100% had a genetic status consistent with PGT results. The overall clinical outcome of successful live birth for couples at risk of producing offspring with HbE/βthal was 53.33%. Conclusively, combined PGT-M and PGT-A is a useful technology to prevent HbE/βthal disease in the offspring of recessive carriers.
Competing Interests: The authors have declared that no competing interests exist.

Hum Reprod. 2011 Jan;26(1):33-40. (PMID: 20966462)
Expert Rev Mol Diagn. 2017 Jun;17(6):611-621. (PMID: 28459185)
Fertil Steril. 2018 Apr;109(4):627-632. (PMID: 29605407)
Best Pract Res Clin Obstet Gynaecol. 2017 Jul;42:2-10. (PMID: 28533154)
Biol Blood Marrow Transplant. 2018 Aug;24(8):1575-1580. (PMID: 29649618)
Southeast Asian J Trop Med Public Health. 1992;23 Suppl 2:1-6. (PMID: 1298980)
Blood. 2014 Jul 17;124(3):334-43. (PMID: 24914138)
Expert Rev Mol Diagn. 2017 Mar;17(3):281-291. (PMID: 28110577)
J Assist Reprod Genet. 2018 Sep;35(9):1605-1612. (PMID: 30074131)
Gynecol Obstet Invest. 2014;77(3):180-5. (PMID: 24603632)
Eur J Hum Genet. 2016 Apr;24(4):469-78. (PMID: 26014425)
Hum Reprod. 2005 Jan;20(1):35-48. (PMID: 15539444)
BMC Womens Health. 2015 Aug 19;15:61. (PMID: 26285703)
J Ovarian Res. 2018 Aug 11;11(1):66. (PMID: 30098598)
Hum Reprod. 2002 Jan;17(1):25-31. (PMID: 11756357)
J Med Assoc Thai. 2008 Nov;91(11):1644-50. (PMID: 19127783)
Semin Reprod Med. 2015 Nov;33(6):422-8. (PMID: 26594869)
Birth Defects Orig Artic Ser. 1987;23(5A):241-8. (PMID: 3689905)
Reprod Biomed Online. 2017 Sep;35(3):264-271. (PMID: 28648921)
Immunotherapy. 2012 Sep;4(9):947-56. (PMID: 23046238)
Cold Spring Harb Perspect Med. 2012 May;2(5):a011825. (PMID: 22553502)
Hematol Oncol Clin North Am. 2010 Dec;24(6):1021-31. (PMID: 21075278)
Reprod Biomed Online. 2018 Aug;37(2):136-144. (PMID: 29853423)
Prenat Diagn. 2010 Jun;30(6):540-6. (PMID: 20509153)
Prenat Diagn. 2001 Mar;21(3):214-22. (PMID: 11260611)
Hum Reprod. 2002 May;17(5):1158-65. (PMID: 11980733)
Front Endocrinol (Lausanne). 2018 Jun 29;9:327. (PMID: 30008696)
Nature. 1980 Dec 4;288(5790):497-9. (PMID: 7442796)
Reproduction. 2018 Jul;156(1):F29-F50. (PMID: 29945889)
Eur J Hum Genet. 2008 Mar;16(3):290-9. (PMID: 18091772)
Prenat Diagn. 2013 May;33(5):477-83. (PMID: 23553531)
Genet Test. 1998;2(1):43-53. (PMID: 10464596)
J Assist Reprod Genet. 2017 Jan;34(1):109-116. (PMID: 27815806)
Hematol Oncol Clin North Am. 2018 Apr;32(2):165-175. (PMID: 29458724)
Baillieres Clin Haematol. 1998 Mar;11(1):215-38. (PMID: 10872479)
Cold Spring Harb Perspect Med. 2013 May 01;3(5):a011700. (PMID: 23637309)
Fertil Steril. 2016 May;105(5):1307-1313. (PMID: 26868992)
J Assist Reprod Genet. 1998 May;15(5):219-25. (PMID: 9604751)
Hum Reprod. 2007 May;22(5):1443-9. (PMID: 17261575)
Nature. 1982 Dec 23;300(5894):768-9. (PMID: 7177196)
Prenat Diagn. 2003 Aug;23(8):646-51. (PMID: 12913871)
Curr Opin Pediatr. 2017 Dec;29(6):634-639. (PMID: 28922317)
Curr Opin Hematol. 2000 Mar;7(2):106-12. (PMID: 10698297)
J Pediatr Hematol Oncol. 2000 Nov-Dec;22(6):552-7. (PMID: 11132229)
J Assist Reprod Genet. 1999 Apr;16(4):207-11. (PMID: 10224564)

0 (beta-Globins)
9034-61-1 (Hemoglobin E)

Date Created: 20191122 Date Completed: 20200319 Latest Revision: 20200319

20250114

PMC6872132

10.1371/journal.pone.0225457

31751397